In the monarcHER phase II study, patients with HER2-positive and HR-positive advanced breast cancer who had received at least 2 prior HER2-target therapies were treated with trastuzumab plus fulvestrant and abecile. This evidence concerns the gene ERBB2 and breast cancer.